MITO News and Press, Stealth BioTherapeutics Corp.

Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...

Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...

Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...

Stealth BioTherapeutics ( NASDAQ: MITO ) said on Friday Robert Weiskopf, its chief financial officer, is leaving the company effective September 30. Weiskopf joined Stealth in 2019 following the initial public offering. For further details see: Stealth Biotherape...

Stealth BioTherapeutics Announces Departure of Chief Financial Officer PR Newswire BOSTON , Sept. 30, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commer...

Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events PR Newswire BOSTON , Sept. 15, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development, and...

Stealth BioTherapeutics ( NASDAQ: MITO ) on Monday said it had agreed to go private by being acquired by Morningside Venture (I) Investments, over a month after the clinical-stage biotech received the investment firm's preliminary proposal. MITO stock jumped 19.9% to $...

Stealth BioTherapeutics Corp Enters Definitive Agreement for Going Private Transaction PR Newswire BOSTON , Aug. 1, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, dev...

This seems to be an interesting going private setup currently offering a 10% upside. Majority shareholder Morningside is acquiring the remaining 33% stake in a nanocap biopharmaceutical company Stealth BioTherapeutics. The buyer has indicated that it wants to complete the transact...

A clinical-stage biotechnology company, Stealth BioTherapeutics ( NASDAQ: MITO ) received a letter from Nasdaq on July 7, 2022 for not meeting with minimum bid price and market value of listed securities requirements. Company requests an appeal, trading of the com...